Dine Brands Unveils Dual-Branded Applebee's-IHOP Restaurant Model for Nationwide Expansion

Dine Brands is expanding its Applebee's-IHOP combo restaurant model in the US, aiming to capture and serve customers throughout every daypart. The dual-branded model allows for a single kitchen, cross-trained staff, and a streamlined menu featuring 105 top-selling items from both brands. This strategy has proven profitable, with franchise owners earning two to three times more than single IHOP locations. Dine Brands plans to have 10-12 dual-brands by the end of the year and significantly more in 2026.

The U.S. Food and Drug Administration (FDA) has approved BRINSUPRI™ (brensocatib) as the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB), a serious and chronic lung disease. The approval marks a significant milestone in the treatment landscape for NCFB, which affects approximately 500,000 patients in the U.S. alone [1].

BRINSUPRI, a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor, targets neutrophilic inflammation, a key driver of chronic airway inflammation in NCFB. The drug is available in 10 mg and 25 mg doses and is administered once daily. The approval is based on data from Phase 3 and Phase 2 clinical trials, which demonstrated significant reductions in annual exacerbation rates and improvements in lung function compared to placebo [1].

The FDA approval of BRINSUPRI represents a potential paradigm shift in the treatment of NCFB. Doreen Addrizzo-Harris, M.D., FCCP, Director of the NYU Langone Health Bronchiectasis and NTM Program, noted that the drug directly targets the root cause of bronchiectasis exacerbations and could become the new standard of care [1].

Insmed Incorporated, the biopharmaceutical company that developed BRINSUPRI, plans to file applications for the drug with regulatory agencies in Europe, Japan, and other territories. Commercial launches are anticipated in 2026, pending approval in each region. BRINSUPRI is now available in the U.S. by prescription through a comprehensive specialty pharmacy network [1].

The approval of BRINSUPRI highlights the growing focus on innovative therapies for rare and serious diseases. As more treatments become available, patients and healthcare providers will have additional options to manage NCFB and improve patient outcomes.

References:
[1] https://www.streetinsider.com/PRNewswire/FDA+Approves+BRINSUPRI%E2%84%A2+%28brensocatib%29+as+the+First+and+Only+Treatment+for+Non-Cystic+Fibrosis+Bronchiectasis%2C+a+Serious%2C+Chronic+Lung+Disease/25186812.html